Press Releases

EMERYVILLE, Calif. , Nov. 9, 2022 /PRNewswire/ --  Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer , Chief Executive Officer, and Kelly MacDonald , Chief Financial

Q3 2022 total revenue of $167.7 million , up 55% from $108.3 million for Q3 2021 HEPLISAV-B ®  vaccine net product revenue of $37.5 million, up 65% from $22.7 million for Q3 2021 CpG 1018 ® adjuvant net product revenue of $126.3 million , up 50% from $84.3 million for Q3 2021 Reiterates guidance

EMERYVILLE, Calif. , Oct. 20, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter financial results on Thursday, November 3, 2022 , after the U.S.

EMERYVILLE, Calif. , Oct. 14, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer , Chief Executive Officer, will present at the H.C.

EMERYVILLE, Calif. , Sept. 12, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, in collaboration with the U.S. Department of Defense's (DOD) Joint Program Executive Office for

EMERYVILLE, Calif. , Sept. 8, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer , Chief Executive Officer, will participate in a virtual fireside

Q2 2022 total revenue of $256.5 million , up 386% from $52.8 million for Q2 2021 HEPLISAV-B ®  vaccine net product revenue of $32.7 million, up 139% from $13.7 million for Q2 2021 CpG 1018 ® adjuvant net product revenue of $222.6 million , up 471% from $39.0 million for Q2 2021 On track for second

EMERYVILLE, Calif. , July 21, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter financial results on Thursday, August 4, 2022 , after the U.S.

EMERYVILLE, Calif. , May 25, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer , Chief Executive Officer and Kelly MacDonald , Chief Financial

EMERYVILLE, Calif. , May 16, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer , Chief Executive Officer, will present at the H.C.